SMARCB1-SWN related nerve sheath tumor immortalized cell line and construction method and application thereof

By transfecting hTERT and SV40T into primary cells of SMARCB1-SWN-associated schwannoma, an immortalized cell line of SMARCB1-SWN-associated schwannoma and primary cells was constructed, which solved the difficulty in curing SMARCB1-SWN-associated schwannoma and primary cells in the prior art. The problem of cell aging provides an efficient preclinical research model and supports the validation of disease research and treatment options.

CN118931841APending Publication Date: 2024-11-12BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411115896.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to cure SMARCB1-SWN-related schwannoma through a single surgery, and primary cells directly extracted from patients have aging and demise after several passages, which cannot meet the research needs, and lacks efficient preclinical models for exploration. Treatment plan.

Method used

By transfecting the exogenous immortalized genes hTERT and SV40T into primary cells of SMARCB1-SWN-associated schwannoma, cells were introduced using lentiviral vectors, positive clones were screened and passaged, and sustainable proliferation of SMARCB1-SWN-associated schwannomas were constructed. Immortalized cell line NF3-Sch-Llab-1.

Benefits of technology

Successfully constructed the immortalized cell line of SMARCB1-SWN-related schwannoma, providing a preclinical research model with good homogeneity and easy operation, meeting the research needs for SMARCB1-SWN disease, and supporting the verification and target of treatment plans. filter.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931841A_ABST
    Figure CN118931841A_ABST
Patent Text Reader

Abstract

The embodiment of the invention discloses an SMARCB1-SWN related nerve sheath tumor immortalized cell line as well as a construction method and application thereof. The immortalized cell line NF3-Sch-Llab-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number of the immortalized cell line NF3-Sch-Llab-1 is CGMCC No.45802, and the preservation time is January 10, 2024. According to the invention, exogenous immortalized genes hTERT and SV40T are introduced into SMARCB1 type neurofibromatosis related sphingoma cells through a lentiviral vector, a strain of SMARCB1 type neurofibromatosis related sphingoma immortalized cell line capable of continuously proliferating and passing is successfully constructed, and the effectiveness of the construction method is proved. The invention provides a preclinical research model which is good in homogeneity and simple and convenient to operate for researches in related fields of SMARCB1 type neurofibromatosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The embodiments of the present invention relate to the field of cell engineering technology, and specifically to a SMARCB1-SWN related schwannoma immortalized cell line and a construction method and application thereof. Background Art

[0002] SMARCB1-related schwannomatosis (SMARCB1-SWN) is an autosomal dominant genetic disease caused by mutations in the SMARCB1 gene on chromosome 22q, resulting in multiple lesions in multiple systems. Its clinical manifestations include multiple schwannomas in the central and peripheral nervous systems. Since the above lesions continue to progress in the course of SMARCB1-SWN, it is difficult to achieve a radical cure through a single surgical treatment. Therefore, it is urgent to explore systemic treatment options to reduce the tumor burden of patients.

[0003] To further explore the treatment of SMARCB1-SWN, accurate and efficient SMARCB1-SWN preclinical models are needed as research tools to reveal the pathogenesis, disease progression, tumor heterogeneity and therapeutic targets. Preclinical models mainly include immortalized cell lines, transplanted tumor animal models and gene-edited animal models, which can verify the efficacy, toxicity and adverse reactions of treatment plans from multiple angles. Cell lines are commonly used, relatively inexpensive and easy to operate models. Most primary cells directly extracted from patients age and die after several passages, which cannot meet research needs. Therefore, it is necessary to construct immortalized cell lines with unlimited proliferation ability to continuously provide research models with good homogeneity. Summary of the invention

[0004] To this end, the embodiments of the present invention provide a SMARCB1-SWN related schwannoma immortalized cell line and its construction method and application. The cell line can proliferate and be passaged continuously with no difference between cells, providing an experimental basis for research in the field of SMARCB1 type neurofibromatosis.

[0005] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:

[0006] According to the first aspect of an embodiment of the present invention, the present invention provides a SMARCB1-SWN-related schwannoma immortalized cell line NF3-Sch-Llab-1, which is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with a deposit number of CGMCC No.45802 and a deposit time of January 10, 2024.

[0007] According to the second aspect of an embodiment of the present invention, the present invention provides a method for constructing a SMARCB1-SWN-related schwannoma immortalized cell line as described above, transfecting exogenous immortalization genes hTERT and SV40T into SMARCB1-SWN-related schwannoma primary cells, screening positive clones and subculturing to obtain a SMARCB1-SWN-related schwannoma immortalized cell line.

[0008] Further, the method comprises:

[0009] SMARCB1-SWN-related schwannoma primary cells were inoculated into six-well plates, and exogenous immortalization genes hTERT and SV40T were introduced into the cells using lentiviral vectors. After culturing in an incubator at 37°C and 5% CO2 for 12 h, fresh culture medium was replaced and continued to be cultured;

[0010] 1 μg / mL puromycin was used continuously for one week to select the successfully infected cells. After the cells were observed to be full grown, they were subcultured. If the cells continued to proliferate and be subcultured for more than 20 generations, the immortalized cell line was considered to be successfully established.

[0011] Furthermore, the culture medium is: DMEM complete culture medium containing 10% fetal bovine serum.

[0012] Furthermore, the method for preparing SMARCB1-SWN related schwannoma primary cells comprises the following steps:

[0013] 1) Add digestive enzymes to fresh SMARCB1-SWN-related schwannoma specimens and place in an incubator at 37°C and 5% CO2 for 2-4 hours;

[0014] 2) Filter to remove undigested debris, collect the cell filtrate, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant;

[0015] 3) Add red blood cell lysis buffer to the precipitate, let it stand for 2 minutes, then add 10 mL PBS to resuspend, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant;

[0016] 4) Add 10 mL of PBS to the precipitate to resuspend it, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant;

[0017] 5) Add DMEM complete medium containing 10% fetal bovine serum to the precipitate to resuspend it, transfer it to a culture dish, and culture it in an incubator at 37° C. and 5% CO 2 ;

[0018] 6) The medium was changed every 48-72 hours, the cells were observed under a microscope, and schwannoma cell clones were selected for expansion culture to obtain SMARCB1-SWN related schwannoma primary cells.

[0019] Furthermore, the digestive enzyme includes papain, trypsin or collagenase.

[0020] Furthermore, the filtration uses a cell filter with a particle size of 70 μm or 40 μm.

[0021] According to a third aspect of an embodiment of the present invention, the present invention provides a use of the SMARCB1-SWN related schwannoma immortalized cell line as described above, wherein the use is selected from any one of the following:

[0022] a. Prepare SMARCB1-SWN related schwannoma cell or animal models;

[0023] b. preparing a drug for treating SMARCB1-SWN-related schwannoma;

[0024] c. Screening therapeutic targets for SMARCB1-SWN-related schwannoma.

[0025] The embodiments of the present invention have the following advantages:

[0026] The present invention introduces exogenous immortalization genes hTERT (human telomerase reverse transcriptase) and SV40T (SV40 large T antigen) into SMARCB1-SWN related schwannoma primary cells through lentiviral vectors, successfully constructs an immortalized SMARCB1-SWN related schwannoma cell line that can proliferate sustainably, and confirms the effectiveness of the construction method. The present invention provides a preclinical research model with good homogeneity and simple operation for research in the field of SMARCB1-SWN related fields. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.

[0028] Figure 1 The observation results of the P1 generation of the SMARCB1-SWN related schwannoma primary cell line provided by the present invention;

[0029] Figure 2 The immunofluorescence results of specific antigens of schwannoma cells of the SMARCB1-SWN related schwannoma primary cell line P1 provided by the present invention;

[0030] Figure 3 The comparison results of the relative expression of hTERT gene provided by the present invention;

[0031] Figure 4 The comparison results of the relative expression of the SV40T gene provided by the present invention;

[0032] Figure 5 The present invention provides the observation results of the SMARCB1-SWN related schwannoma immortalized cell line P35. DETAILED DESCRIPTION

[0033] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0034] Example 1 Isolation and culture of SMARCB1-SWN related schwannoma primary cells

[0035] 1. Isolation and culture of primary SMARCB1-SWN related schwannoma cells

[0036] 1) Take fresh SMARCB1-SWN-related schwannoma specimens (Table 1) removed by surgery, keep them sterile, and transport them to the laboratory ultra-clean cell workbench at 4°C.

[0037] Table 1 Peripheral blood high-throughput sequencing results of the corresponding donors

[0038]

[0039] 2) Rinse the specimen with PBS, remove blood stains and electrocoagulation burn sites, place in a 100 mm culture dish, and cut into pieces of approximately 1 mm*1 mm.

[0040] 3) Add 10 mL of 20 U / mL papain to 0.5 g of the sample and place in an incubator at 37°C and 5% CO2 for digestion for 4 hours.

[0041] 4) Filter with a 70 μm cell strainer to remove undigested debris, collect the cell filtrate, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.

[0042] 5) Add red blood cell lysis buffer to the precipitate, let it stand for 2 minutes, then add 10 mL of PBS to resuspend, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.

[0043] 6) Add 10 mL of PBS to the precipitate and resuspend it. Centrifuge at 1000 rpm for 5 minutes and discard the supernatant.

[0044] 7) Add DMEM complete medium containing 10% fetal bovine serum to the precipitate to resuspend it, transfer it to a culture dish, and culture it in an incubator at 37° C. and 5% CO 2 .

[0045] 8) The medium was changed every 72 hours, the cells were observed under a microscope, and the schwannoma cell clones were selected for expansion culture to obtain SMARCB1-SWN related schwannoma primary cells P1 ( Figure 1 ).

[0046] 2. Identification of SMARCB1-SWN-related schwannoma primary cells

[0047] The specific antigen SOX10 of schwannoma cells was selected for immunofluorescence staining. The red fluorescence indicated the expression of SOX10 in the cytoplasm, and the blue fluorescence was DAPI indicating the cell nucleus. The cells were identified as schwannoma cells ( Figure 2 ).

[0048] Example 2 Establishment and culture of SMARCB1-SWN related schwannoma immortalized cell line

[0049] 1. Establishment and culture of SMARCB1-SWN-related schwannoma immortalized cell lines

[0050] 1) Prepare DNA / Lentifectin virus packaging mixture: Add 140μg pLenti SV40T Vector / pLenti hTERT Vector expression plasmid and 168μg lentiviral transfection auxiliary plasmid 2nd Generation Packaging Mix to 10ml serum-free medium, mix well, and incubate at room temperature for 5min. Add 900μl Lentifectin transfection reagent to another 10ml serum-free medium, mix well, and incubate at room temperature for 5min. Mix the above plasmid mixed solution and Lentifectin mixed solution, incubate at room temperature for 20min, and then add 40ml serum-free medium to obtain a DNA / Lentifectin mixture. Remove the old medium from the 293T cell culture dish, add the DNA / Lentifectin mixture, and culture in an incubator at 37°C and 5% CO2. After 24 hours, fresh DMEM medium containing 10% fetal bovine serum was replaced. After 48 hours, the medium was collected, filtered through a 0.45 μm PVDF membrane, and centrifuged at 10,000 g for 4 hours to collect and obtain SV40T lentiviral particles and hTERT lentiviral particles.

[0051] 2) The SMARCB1-SWN-related schwannoma primary cells of passage P1 were inoculated into a six-well plate. According to the optimal MOI value determined in the preliminary experiment of 10, 15 μl of the SV40T-expressing lentiviral particles and hTERT lentivirus obtained in step 1 were added to the six-well plate, gently shaken to mix, and cultured in an incubator at 37°C, 5% CO2 for 12 h, and then replaced with fresh DMEM complete medium containing 10% fetal bovine serum for continued culture.

[0052] 3) Use 1 μg / mL of puromycin for one week to select the successfully infected cells, and then subculture the cells after they have grown to full size. If the cells continue to proliferate and subculture for more than 20 generations, the immortalized cell line is considered to have been successfully established.

[0053] The cell line that has proliferated and passaged for more than 20 generations was preserved and named NF3-Sch-Llab-1, with the preservation number CGMCC No.45802 and the preservation date January 10, 2024.

[0054] 2. Detection of SMARCB1-SWN-related schwannoma immortalized cell lines

[0055] (1) hTERT and SV40T were detected by fluorescence quantitative PCR technology in the P3 generation of SMARCB1-SWN-related schwannoma primary cell line and the P30 generation of SMARCB1-SWN-related schwannoma immortalized cell line.

[0056] RNA was extracted from the primary cell line P3 and the immortalized cell line P30, respectively, and reverse transcribed into cDNA, which was used as a template for DNA amplification, and then Real-time PCR was used for fluorescence quantitative analysis.

[0057] The results showed that hTERT and SV40T were correctly expressed in SMARCB1-SWN-related schwannoma immortalized cell lines ( Figure 3-4 ).

[0058] (2) The SMARCB1-SWN-related schwannoma primary cell line and the SMARCB1-SWN-related schwannoma immortalized cell line were subjected to genotype short tandem repeat sequence (STR) detection. The results are shown in Table 2 below.

[0059] Table 2

[0060]

[0061]

[0062] The results showed that the STR of SMARCB1-SWN-related schwannoma primary cell line and SMARCB1-SWN-related schwannoma immortalized cell line were completely matched, confirming that the two cell lines were from the same tissue and there was no cross-contamination.

[0063] (3) In vitro cell culture and cell morphology observation

[0064] The SMARCB1-SWN-related schwannoma immortalized cell line cultured in vitro was subcultured to the 35th generation, and the cells proliferated and were subcultured approximately every 3 days, showing good cell activity. Under the bright field microscope, the cells were vortex-shaped and grew in a single layer ( Figure 5 ).

[0065] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. A SMARCB1-SWN related schwannoma immortalized cell line NF3-Sch-Llab-1, characterized in that: It is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with the deposit number CGMCC No.45802 and the deposit date January 10, 2024.

2. A method for constructing a SMARCB1-SWN-related schwannoma immortalized cell line as claimed in claim 1, characterized in that: Exogenous immortalization genes hTERT and SV40T were transfected into SMARCB1-SWN-related schwannoma primary cells, and positive clones were screened and subcultured to obtain SMARCB1-SWN-related schwannoma immortalized cell lines.

3. The construction method according to claim 2, characterized in that: The method comprises: SMARCB1-SWN-related schwannoma primary cells were inoculated into six-well plates, and exogenous immortalization genes hTERT and SV40T were introduced into the cells using lentiviral vectors. After culturing in an incubator at 37°C and 5% CO2 for 12 h, fresh culture medium was replaced and continued to be cultured; 1 μg / mL puromycin was used continuously for one week to select the successfully infected cells. After the cells were observed to be full grown, they were subcultured. If the cells continued to proliferate and be subcultured for more than 20 generations, the immortalized cell line was considered to be successfully established.

4. The construction method according to claim 3, characterized in that: The culture medium is: DMEM complete culture medium containing 10% fetal bovine serum.

5. The construction method according to claim 3, characterized in that: The method for preparing SMARCB1-SWN related schwannoma primary cells comprises the following steps: 1) Add digestive enzymes to fresh SMARCB1-SWN-related schwannoma specimens and place in an incubator at 37°C and 5% CO2 for 2-4 hours; 2) Filter to remove undigested debris, collect the cell filtrate, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant; 3) Add red blood cell lysis buffer to the precipitate and let it stand for 2 minutes, then add 10 mL PBS to resuspend, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant; 4) Add 10 mL of PBS to the precipitate to resuspend it, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant; 5) Add DMEM complete medium containing 10% fetal bovine serum to the precipitate to resuspend it, transfer it to a culture dish, and culture it in an incubator at 37° C. and 5% CO 2 ; 6) The medium was changed every 48-72 hours, the cells were observed under a microscope, and schwannoma cell clones were selected for expansion culture to obtain SMARCB1-SWN related schwannoma primary cells.

6. The construction method according to claim 5, characterized in that: The digestive enzymes include papain, trypsin or collagenase.

7. The construction method according to claim 5, characterized in that: The filtration uses a cell filter with a particle size of 70 μm or 40 μm.

8. The use of the SMARCB1-SWN related schwannoma immortalized cell line according to claim 1, characterized in that: The use is selected from any one of the following: a. Prepare SMARCB1-SWN related schwannoma cell or animal models; b. preparing a drug for treating SMARCB1-SWN-related schwannoma; c. Screening therapeutic targets for SMARCB1-SWN-related schwannoma.